{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T05:24:25Z","timestamp":1731043465570,"version":"3.28.0"},"reference-count":20,"publisher":"Texas Heart Institute Journal","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"abstract":"<jats:title>Abstract<\/jats:title>\n        <jats:p>Portopulmonary hypertension is a rare condition with a poor prognosis. Prompt management is essential for liver transplantation eligibility, a potentially curative option. This report presents a case of severe portopulmonary hypertension that resolved with a conservative therapeutic regimen of tadalafil, macitentan, and inhaled treprostinil, which ultimately enabled successful liver transplantation. There was no recurrence of pulmonary hypertension after transplantation, and the patient was weaned off most pulmonary arterial hypertension therapies. This case report is the first to provide evidence that inhaled treprostinil is a safe and effective alternative to continuous intravenous prostacyclins in portopulmonary hypertension.<\/jats:p>","DOI":"10.14503\/thij-23-8209","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T14:55:58Z","timestamp":1710428158000},"source":"Crossref","is-referenced-by-count":0,"title":["Resolution of Severe Portopulmonary Hypertension With Inhaled Treprostinil and Liver Transplantation"],"prefix":"10.14503","volume":"51","author":[{"given":"Alex J.","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Medicine, Kaiser Permanente San Francisco Medical Center, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choon Hwa","family":"Goh","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5628","reference":[{"issue":"11","key":"b1","series-title":"J Am Heart Assoc.","article-title":"Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials","volume":"5","author":"Wei\n              A","year":"2016","unstructured":"Wei\n              A\n            , GuZ, LiJ, et al.\n          Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials. J Am Heart Assoc.2016;5(11):e003896. doi:10.1161\/JAHA.116.003896"},{"issue":"9419","key":"b2","series-title":"Lancet.","first-page":"1461","article-title":"Portopulmonary hypertension and hepatopulmonary syndrome","volume":"363","author":"Hoeper\n              MM","year":"2004","unstructured":"Hoeper\n              MM\n            , KrowkaMJ, StrassburgCP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet.2004;363(9419):1461-1468. doi:10.1016\/S0140-6736(04)16107-2"},{"issue":"5","key":"b3","series-title":"Eur Respir J.","first-page":"861","article-title":"ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-hepatic vascular disorders (PHD)","volume":"24","author":"Rodr\u00edguez-Roisin\n              R","year":"2004","unstructured":"Rodr\u00edguez-Roisin\n              R\n            , KrowkaMJ, Herv\u00e9P, FallonMB; ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J.2004;24(5):861-880. doi:10.1183\/09031936.04.00010904"},{"issue":"8","key":"b4","series-title":"Angiology.","first-page":"802","article-title":"Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver transplantation","volume":"61","author":"Pellicelli\n              AM","year":"2010","unstructured":"Pellicelli\n              AM\n            , BarbaroG, PuotiC, et al.\n          Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver transplantation. Angiology.2010;61(8):802-806. doi:10.1177\/0003319710369101"},{"issue":"4","key":"b5","series-title":"Eur Respir J.","first-page":"1700745","article-title":"Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases: highlights from basic research to therapy","volume":"51","author":"Huertas\n              A","year":"2018","unstructured":"Huertas\n              A\n            , GuignabertC, Barber\u00e0JA, et al.\n          Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases: highlights from basic research to therapy. Eur Respir J.2018;51(4):1700745. doi:10.1183\/13993003.00745-2017"},{"issue":"5","key":"b6","series-title":"Clin J Gastroenterol.","first-page":"387","article-title":"Vascular syndromes in liver cirrhosis","volume":"12","author":"Shenoda\n              B","year":"2019","unstructured":"Shenoda\n              B\n            , BoselliJ. Vascular syndromes in liver cirrhosis. Clin J Gastroenterol.2019;12(5):387-397. doi:10.1007\/s12328-019-00956-0"},{"issue":"5","key":"b7","series-title":"Hepatology.","first-page":"1701","article-title":"Vasomodulators and liver transplantation for portopulmonary hypertension: evidence from a systematic review and meta-analysis","volume":"72","author":"Deroo\n              R","year":"2020","unstructured":"Deroo\n              R\n            , Tr\u00e9poE, HolvoetT, et al.\n          Vasomodulators and liver transplantation for portopulmonary hypertension: evidence from a systematic review and meta-analysis. Hepatology.2020;72(5):1701-1716. doi:10.1002\/hep.31164"},{"issue":"3","key":"b8","series-title":"Eur Respir J.","first-page":"563","article-title":"Sildenafil treatment for portopulmonary hypertension","volume":"28","author":"Reichenberger\n              F","year":"2006","unstructured":"Reichenberger\n              F\n            , VoswinckelR, StevelingE, et al.\n          Sildenafil treatment for portopulmonary hypertension. Eur Respir J.2006;28(3):563-567. doi:10.1183\/09031936.06.00030206"},{"issue":"4","key":"b9","series-title":"J Heart Lung Transplant.","first-page":"498","article-title":"Novel use of sildenafil in the treatment of portopulmonary hypertension","volume":"24","author":"Chua\n              R","year":"2005","unstructured":"Chua\n              R\n            , KeoghA, MiyashitaM. Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant.2005;24(4):498-500. doi:10.1016\/j.healun.2004.01.017"},{"issue":"1","key":"b10","series-title":"Eur Respir J.","first-page":"96","article-title":"Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension","volume":"41","author":"Savale\n              L","year":"2013","unstructured":"Savale\n              L\n            , MagnierR, Le PavecJ, et al.\n          Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J.2013;41(1):96-103. doi:10.1183\/09031936.00117511"},{"issue":"1","key":"b11","series-title":"Chest.","first-page":"109","article-title":"Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension","volume":"139","author":"Cartin-Ceba\n              R","year":"2011","unstructured":"Cartin-Ceba\n              R\n            , SwansonK, IyerV, WiesnerRH, KrowkaMJ. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest.2011;139(1):109-114. doi:10.1378\/chest.10-0574"},{"issue":"7","key":"b12","series-title":"Lancet Respir Med.","first-page":"594","article-title":"Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial","volume":"7","author":"Sitbon\n              O","year":"2019","unstructured":"Sitbon\n              O\n            , BoschJ, CottreelE, et al.\n          Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med.2019;7(7):594-604. doi:10.1016\/S2213-2600(19)30091-8"},{"issue":"4","key":"b13","series-title":"Transplantation.","first-page":"604","article-title":"Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension","volume":"63","author":"Kuo\n              PC","year":"1997","unstructured":"Kuo\n              PC\n            , JohnsonLB, PlotkinJS, HowellCD, BartlettST, RubinLJ. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation.1997;63(4):604-606. doi:10.1097\/00007890-199702270-00020"},{"issue":"3","key":"b14","series-title":"Hepatology.","first-page":"641","article-title":"Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension","volume":"30","author":"Krowka\n              MJ","year":"1999","unstructured":"Krowka\n              MJ\n            , FrantzRP, McGoonMD, SeversonC, PlevakDJ, WiesnerRH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology.1999;30(3):641-648. doi:10.1002\/hep.510300307"},{"issue":"1","key":"b15","series-title":"Chest.","first-page":"130","article-title":"Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension","volume":"135","author":"Chin\n              KM","year":"2009","unstructured":"Chin\n              KM\n            , ChannickRN, de LemosJA, KimNH, TorresF, RubinLJ. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. Chest.2009;135(1):130-136. doi:10.1378\/chest.08-1323"},{"issue":"12","key":"b16","series-title":"J Gastroenterol.","first-page":"1222","article-title":"Use of aerosolized inhaled iloprost in the treatment of portopulmonary hypertension","volume":"39","author":"Halank\n              M","year":"2004","unstructured":"Halank\n              M\n            , MarxC, MiehlkeS, HoeffkenG. Use of aerosolized inhaled iloprost in the treatment of portopulmonary hypertension. J Gastroenterol.2004;39(12):1222-1223. doi:10.1007\/s00535-004-1478-7"},{"issue":"7","key":"b17","series-title":"Transplantation.","first-page":"1440","article-title":"International Liver Transplant Society practice guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension","volume":"100","author":"Krowka\n              MJ","year":"2016","unstructured":"Krowka\n              MJ\n            , FallonMB, KawutSM, et al.\n          International Liver Transplant Society practice guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension. Transplantation.2016;100(7):1440-1452. doi:10.1097\/TP.0000000000001229"},{"issue":"4","key":"b18","series-title":"Liver Transpl.","first-page":"443","article-title":"Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation","volume":"6","author":"Krowka\n              MJ","year":"2000","unstructured":"Krowka\n              MJ\n            , PlevakDJ, FindlayJY, RosenCB, WiesnerRH, KromRA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl.2000;6(4):443-450. doi:10.1053\/jlts.2000.6356"},{"key":"b19","series-title":"Liver Transpl.","first-page":"S114","article-title":"Model for end-stage liver disease (MELD) exception for portopulmonary hypertension","volume":"12","author":"Krowka\n              MJ","year":"2006","unstructured":"Krowka\n              MJ\n            , FallonMB, MulliganDC, GishRG. Model for end-stage liver disease (MELD) exception for portopulmonary hypertension. Liver Transpl.2006;12(12 Suppl 3):S114-S116. doi:10.1002\/lt.20975"},{"issue":"4","key":"b20","series-title":"Transplantation.","first-page":"524","article-title":"Indications for and outcomes after combined lung and liver transplantation: a single-center experience on 13 consecutive cases","volume":"85","author":"Grannas\n              G","year":"2008","unstructured":"Grannas\n              G\n            , NeippM, HoeperMM, et al.\n          Indications for and outcomes after combined lung and liver transplantation: a single-center experience on 13 consecutive cases. Transplantation.2008;85(4):524-531. doi:10.1097\/TP.0b013e3181636f3f"}],"container-title":["Texas Heart Institute Journal"],"original-title":[],"link":[{"URL":"https:\/\/thij.kglmeridian.com\/view\/journals\/thij\/51\/1\/article-e238209.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/thij\/article-pdf\/doi\/10.14503\/THIJ-23-8209\/3410982\/i1526-6702-51-1-e238209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thij.kglmeridian.com\/downloadpdf\/journals\/thij\/51\/1\/article-e238209.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thij.kglmeridian.com\/downloadpdf\/journals\/thij\/51\/1\/article-e238209.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T15:38:47Z","timestamp":1730993927000},"score":1,"resource":{"primary":{"URL":"https:\/\/thij.kglmeridian.com\/view\/journals\/thij\/51\/1\/article-e238209.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":20,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.14503\/thij-23-8209","relation":{},"ISSN":["1526-6702","0730-2347"],"issn-type":[{"type":"electronic","value":"1526-6702"},{"type":"print","value":"0730-2347"}],"subject":[],"published":{"date-parts":[[2024]]}}}